You are here
June 29, 2015
HIV Vaccine Progress in Animal Studies
At a Glance
- Three research teams achieved important steps needed to prompt the immune system to produce antibodies against HIV.
- The results suggest that an effective HIV vaccine strategy will most likely require a sequence of different immunizations.
HIV, the virus that causes AIDS, attacks and destroys immune cells. For those infected with HIV, antiretroviral therapy helps to prevent the virus from multiplying. But scientists haven’t yet been able to design a vaccine that protects people from HIV.
Most vaccines work by triggering the immune system to produce antibodies that help beat back infections. The HIV surface protein known as Env is a major target for potential HIV vaccines. One challenge in developing a vaccine is that Env can mutate rapidly. These changes to the protein’s surface help it to evade the immune system. The surface of the Env protein is also protected by a coat of sugar molecules that helps shield it from the immune system. Env is a “trimeric” spike-shaped protein, with 3 identical molecules, each with a cap-like region called glycoprotein 120 (gp120) atop a stem.
Researchers have identified human antibodies that can neutralize multiple strains of HIV by binding to a small portion of gp120. The antibodies fail to control the virus in the people who make them, but they can prevent infection in animal models. Researchers have been studying these antibodies in the hope of designing a vaccine that prompts the human immune system to mount an effective defense against HIV.
Antibodies are made by B cells in response to infectious agents. Precursor B cells “mature” to better recognize foreign molecules through a process of multiple rounds of mutation and competitive selection over generations of cells. Past studies have found that the type of precursor B cells that later evolve to produce broadly neutralizing antibodies aren’t activated by native HIV glycoproteins. Three studies published on June 18, 2015, in Science and Cell described advances in understanding how to coax these cells into B cells capable of producing antibodies to neutralize HIV. The studies were funded in part by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
Scientists from Scripps Research Institute engineered a nanoparticle, called eOD-GT8 60mer, specifically designed to initiate the process of B cell maturation. They tested this nanoparticle alongside a native form of the HIV envelope protein in mice that were genetically modified to produce precursors of the VRC01 antibody. This antibody, first isolated in 2010 by NIAID researchers, neutralizes a wide range of HIV strains by binding to a small portion of gp120. As reported in Science, the researchers found that the nanoparticle, but not the native protein, prompted a robust response from precursor B cells, beginning the process of producing broadly neutralizing antibodies.
In a second study, published in Cell, scientists at Rockefeller University, along with Scripps and Weill Medical College of Cornell teams, tested the same proteins in 2 other genetically modified mice, one engineered to produce precursors of an antibody similar to VRC01 (called 3BNC60) and another to produce a more mature version of that antibody. These investigators also found that the eOD-GT8 nanoparticle could activate precursor B cells while the native protein could not. In the more mature B cell mouse, however, the nanoparticle didn’t activate the B cells to further mature whereas the native protein did.
In the third article, published in Science, a team led by researchers at Weill Medical College of Cornell tested the same native envelope protein studied in the other 2 studies. The protein, called BG505 SOSIP, was designed to retain a structure similar to the native trimer on the virus surface. In both rabbits and rhesus macaques, immunization induced antibodies that could neutralize a relatively neutralization-resistant HIV strain. However, the breadth of this reactivity was limited. These results show that native Env proteins have the potential to induce HIV neutralizing antibodies, but more research will be needed to identify how to use native-like proteins to induce broadly neutralizing antibodies.
Taken together, these findings suggest that to produce broadly neutralizing antibodies, an HIV vaccine regimen would likely require one type of protein to prompt precursor B cells to produce antibodies with the potential to be broadly neutralizing and then another, native-like protein to coax development of more mature, neutralizing forms of the antibodies.
“While our results suggest sequential immunizations may make it possible to vaccinate against HIV, we have only just begun to understand how this sequence would work,” says Rockefeller’s Dr. Pia Dosenovic, a co-first author of the Cell paper. “We know the beginning and the end, but we don’t know what should happen in the middle.”
—by Harrison Wein, Ph.D.
- HIV Immunotherapy Promising in First Human Study
- Key HIV Protein Structure Revealed
- Clues to HIV Protection
- Making Antibodies That Neutralize HIV
- Antibodies Protect Human Cells from Most HIV Strains
- HIV and AIDS: Know the Facts
- AIDS Info
Reference: Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Skog PD, Thinnes TC, Bhullar D, Briney B, Menis S, Jones M, Kubitz M, Spencer S, Adachi Y, Burton DR, Schief WR, Nemazee D. Science. 2015 Jun 18. pii: aac5894. [Epub ahead of print]. PMID: 26089355.
HIV-1 neutralizing antibodies induced by native-like envelope trimers. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. Science. 2015 Jun 18. pii: aac4223. [Epub ahead of print]. PMID: 26089353.
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC. Cell. 2015 Jun 18;161(7):1505-15. doi: 10.1016/j.cell.2015.06.003. PMID: 26091035.
Funding: NIH’s National Institute of Allergy and Infectious Diseases (NIAID), National Center for Advancing Translational Sciences (NCATS), and Office of the Director (OD); United States Agency for International Development (USAID); Bill & Melinda Gates Foundation; International AIDS Vaccine Initiative Neutralizing Antibody Consortium and Center; Aids Fonds Netherlands; Canadian Institutes of Health Research; Netherlands Organization for Scientific Research; European Research Council; International AIDS Vaccine Initiative; Howard Hughes Medical Institute; Swedish Research Council; and Helen Hay Whitney Foundation.